We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dose-Dense Chemotherapy Should Be a New Standard in Early Breast Cancer.
- Abstract
The article focuses on the meta-analysis of the Early Breast Cancer Trialists Collaborative Group which states that increasing the dose density of chemotherapy should become a new standard for the treatment of early breast cancer. It states that approaches to dose intensification significantly reduced the rate of recurrence. It highlights the NSABP-B-47 trial which reveals that the addition of trastuzumab to standard adjuvant chemotherapy did not improve disease-free survival (DFS) in patients.
- Subjects
BREAST cancer chemotherapy; BREAST cancer treatment; DRUG dosage; BREAST cancer patients; TRASTUZUMAB; PROGRESSION-free survival
- Publication
Oncology Practice Management, 2018, Vol 8, Issue 2, p16
- ISSN
2164-4403
- Publication type
Article